US HHS Says FDA Aware Of Second Reported Fatal Case Of Severe Liver Failure Due To Sarepta Gene Therapy
ReutersJun 16, 2025 8:53 PM
June 16 (Reuters) -
US HHS-FDA AWARE OF SECOND REPORTED FATAL CASE OF SEVERE LIVER FAILURE DUE TO SAREPTA GENE THERAPY, TREATING SITUATION WITH HIGHEST LEVEL OF CONCERN
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
SpaceX IPO with Dual-Class Shares: Will Musk Secure the 25% Voting Control Denied by Tesla?
TradingKey - SpaceX is preparing for an IPO this year. According to foreign media reports, SpaceX is considering a dual-class share structure for its IPO, which would grant specific shareholders extra voting rights. In other words, Elon Musk could maintain absolute control over the company even if hTradingKey
15 hours ago
Bitcoin Price Prediction 2029-2035: Institutional Accumulation and the U.S. Treasury’s Strategic Reserve Pivot
Explore the 2026 Bitcoin landscape: From the U.S. Strategic Reserve and Michael Saylor’s $75B war chest to Cathie Wood’s 2030 forecast. Is BTC the new Digital Gold?TradingKey
Fri, Feb 13
This $1 Trillion AI Stock Is Getting Ready for 2026: Is Meta a Good Buy?
When ads and commerce are factored in, Meta is building a long-term platform—in Augmented Reality and smart glasses — to get us closer to the future of AI. This device hardware business is less profitable than ads right now, but it could grow the company’s ecosystem and open up new ways for it to maTradingKey
Thu, Feb 12
Is SaaS Dead? The Truth Behind the Software Meltdown, the Missing Floor, and the Peak That’s Not Coming Back
TradingKey - A trillion dollars just vanished from software stocks—this piece breaks down who AI is really killing, who quietly benefits, and why cheap SaaS may be the biggest value trap of this cycle.TradingKey
Thu, Feb 12
